Josh Wolfe - 04 Feb 2026 Form 3 Insider Report for Eikon Therapeutics, Inc. (EIKN)

Role
Director, 10%+ Owner
Signature
/s/ Benjamin Thorner, Attorney-in-Fact
Issuer symbol
EIKN
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
3
Filing time
04 Feb 2026, 21:30:29 UTC
Previous filing
20 Jun 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wolfe Josh Director, 10%+ Owner C/O EIKON THERAPEUTICS, INC., 230 HARRIET TUBMAN WAY, MILLBRAE /s/ Benjamin Thorner, Attorney-in-Fact 04 Feb 2026 0001830001

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EIKN Series A Preferred Stock 04 Feb 2026 Common Stock 1,340,878 See footnote F1, F2
holding EIKN Series A-1 Preferred Stock 04 Feb 2026 Common Stock 1,046,827 See footnote F2, F3
holding EIKN Series A-1 Preferred Stock 04 Feb 2026 Common Stock 335,521 See footnote F3, F4
holding EIKN Series B Preferred Stock 04 Feb 2026 Common Stock 106,785 See footnote F4, F5
holding EIKN Series B Preferred Stock 04 Feb 2026 Common Stock 71,190 See footnote F5, F6
holding EIKN Series B-1 Preferred Stock 04 Feb 2026 Common Stock 709,234 See footnote F4, F7
holding EIKN Series B-1 Preferred Stock 04 Feb 2026 Common Stock 472,822 See footnote F6, F7
holding EIKN Series C Preferred Stock 04 Feb 2026 Common Stock 40,677 See footnote F6, F8
holding EIKN Series C-1 Preferred Stock 04 Feb 2026 Common Stock 194,510 See footnote F6, F9
holding EIKN Series D Preferred Stock 04 Feb 2026 Common Stock 1,376,566 See footnote F6, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2 These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. Peter Hebert and the Reporting Person (the "Individual Lux Managers") are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. The Reporting Person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F3 The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
F4 These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. The Individual Lux Managers are the individual managing members of LCIP II, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. The Reporting Person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F5 The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F6 These shares are held by Lux Total Opportunities, L.P., ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP, and as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. The Reporting Person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F7 The Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
F8 The Series C Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
F9 The Series C-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
F10 The Series D Preferred Stock is convertible into Common Stock on a 1-for 7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series D Preferred Stock will be converted into shares of Common Stock of the Issuer.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney